Allan McLeod
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Allan McLeod has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Sharon J. Hutchinson
Glasgow Caledonian University Glasgow UK
4 shared publications David J. Goldberg
Clinical and Protecting Health Division, Public Health Scotland, Glasgow, G2 7ER, UK; School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, G4 0BA, UK
3 shared publicationsAmanda Weir
Clinical and Protecting Health Division, Public Health Scotland, Glasgow, G2 7ER, UK
2 shared publicationsD. J. Goldberg
School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK
2 shared publications- John Francis Dillon
School of Medicine, University of Dundee, Dundee, UK
2 shared publications - Stephen T. Barclay
Glasgow Royal Infirmary, Glasgow, UK
2 shared publications
Latest Publications
- 30 July 2025
- Published by Elsevier in Public Health
- Vol. 247, 105878
Factors influencing hepatitis C test uptake following exposure to an infected healthcare worker: Insights from a patient notification exercise
- 30 July 2025
- Published by Elsevier in Public Health
- Vol. 247, 105878
Factors influencing hepatitis C test uptake following exposure to an infected healthcare worker: Insights from a patient notification exercise
- Open Access
- 27 June 2022
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 150, 1-29
Liver function tests in primary care provide a key opportunity to diagnose and engage patients with hepatitis C
Since the advent of direct-acting antiviral therapy, the elimination of hepatitis c virus (HCV) as a public health concern is now possible. However, identification of those who remain undiagnosed, and re-engagement of those who are diagnosed but remain untreated, will be essential to achieve this. We examined the extent of HCV infection among individuals undergoing liver function tests (LFT) in primary care. Residual biochemistry samples for 6007 patients, who had venous blood collected in primary care for LFT between July 2016 and January 2017, were tested for HCV antibody. Through data linkage to national and sentinel HCV surveillance databases, we also examined the extent of diagnosed infection, attendance at specialist service and HCV treatment for those found to be HCV positive. Overall HCV antibody prevalence was 4.0% and highest for males (5.0%), those aged 37-50 years (6.2%), and with an ALT result of 70 or greater (7.1%). Of those testing positive, 68.9% had been diagnosed with HCV in the past, 84.9% before the study period. Most (92.5%) of those diagnosed with chronic infection had attended specialist liver services and while 67.7% had ever been treated only 38% had successfully cleared infection. More than half of HCV-positive people required assessment, and potentially treatment, for their HCV infection but were not engaged with services during the study period. LFT in primary care are a key opportunity to diagnose, re-diagnose and re-engage patients with HCV infection and highlight the importance of GPs in efforts to eliminate HCV as a public health concern.
- 27 June 2022
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 150, 1-29
Open AccessLiver function tests in primary care provide a key opportunity to diagnose and engage patients with hepatitis C
Since the advent of direct-acting antiviral therapy, the elimination of hepatitis c virus (HCV) as a public health concern is now possible. However, identification of those who remain undiagnosed, and re-engagement of those who are diagnosed but remain untreated, will be essential to achieve this. We examined the extent of HCV infection among individuals undergoing liver function tests (LFT) in primary care. Residual biochemistry samples for 6007 patients, who had venous blood collected in primary care for LFT between July 2016 and January 2017, were tested for HCV antibody. Through data linkage to national and sentinel HCV surveillance databases, we also examined the extent of diagnosed infection, attendance at specialist service and HCV treatment for those found to be HCV positive. Overall HCV antibody prevalence was 4.0% and highest for males (5.0%), those aged 37-50 years (6.2%), and with an ALT result of 70 or greater (7.1%). Of those testing positive, 68.9% had been diagnosed with HCV in the past, 84.9% before the study period. Most (92.5%) of those diagnosed with chronic infection had attended specialist liver services and while 67.7% had ever been treated only 38% had successfully cleared infection. More than half of HCV-positive people required assessment, and potentially treatment, for their HCV infection but were not engaged with services during the study period. LFT in primary care are a key opportunity to diagnose, re-diagnose and re-engage patients with HCV infection and highlight the importance of GPs in efforts to eliminate HCV as a public health concern.
- 17 December 2020
- Published by Wiley in HIV Medicine
- Vol. 22 (5) , 334-345
Increased case‐finding and uptake of direct‐acting antiviral treatment essential for micro‐elimination of hepatitis C among people living with HIV: a national record linkage study
Objectives: Micro‐elimination of hepatitis C virus (HCV) in people living with HIV (PLHIV) and co‐infected with HCV has been proposed as a key contribution to the overall goal of HCV elimination. While other studies have examined micro‐elimination in HIV‐treated cohorts, few have considered HCV micro‐elimination among those not treated for HIV or at a national level.Methods: Through data linkage of national and sentinel surveillance data, we examined the extent of HCV testing, diagnosis and treatment among a cohort of PLHIV in Scotland identified through the national database of HIV‐diagnosed individuals, up to the end of 2017.Results: Of 5018 PLHIV, an estimated 797 (15%) had never been tested for HCV and 70 (9%) of these had undiagnosed chronic HCV. The odds of never having been tested for HCV were the highest in those not on HIV treatment [adjusted odds ratio (aOR) = 7.21, 95% confidence interval (CI): 5.15–10.10). Overall HCV antibody positivity was 11%, and it was at its highest among people who inject drugs (49%). Most of those with chronic HCV (91%) had attended an HCV treatment clinic but only half had been successfully treated (54% for those on HIV treatment, 12% for those not) by the end of 2017. The odds of never having been treated for HCV were the highest in those not on HIV treatment (aOR = 3.60, 95% CI: 1.59–8.15).Conclusions: Our data demonstrate that micro‐elimination of HCV in PLHIV is achievable but progress will require increased effort to engage and treat those co‐infected, including those not being treated for their HIV.
- 17 December 2020
- Published by Wiley in HIV Medicine
- Vol. 22 (5) , 334-345
Increased case‐finding and uptake of direct‐acting antiviral treatment essential for micro‐elimination of hepatitis C among people living with HIV: a national record linkage study
Objectives: Micro‐elimination of hepatitis C virus (HCV) in people living with HIV (PLHIV) and co‐infected with HCV has been proposed as a key contribution to the overall goal of HCV elimination. While other studies have examined micro‐elimination in HIV‐treated cohorts, few have considered HCV micro‐elimination among those not treated for HIV or at a national level.Methods: Through data linkage of national and sentinel surveillance data, we examined the extent of HCV testing, diagnosis and treatment among a cohort of PLHIV in Scotland identified through the national database of HIV‐diagnosed individuals, up to the end of 2017.Results: Of 5018 PLHIV, an estimated 797 (15%) had never been tested for HCV and 70 (9%) of these had undiagnosed chronic HCV. The odds of never having been tested for HCV were the highest in those not on HIV treatment [adjusted odds ratio (aOR) = 7.21, 95% confidence interval (CI): 5.15–10.10). Overall HCV antibody positivity was 11%, and it was at its highest among people who inject drugs (49%). Most of those with chronic HCV (91%) had attended an HCV treatment clinic but only half had been successfully treated (54% for those on HIV treatment, 12% for those not) by the end of 2017. The odds of never having been treated for HCV were the highest in those not on HIV treatment (aOR = 3.60, 95% CI: 1.59–8.15).Conclusions: Our data demonstrate that micro‐elimination of HCV in PLHIV is achievable but progress will require increased effort to engage and treat those co‐infected, including those not being treated for their HIV.
- Open Access
- 1 June 2020
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 27 (10) , 996-1002
Real‐world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype
Following positive serology, the gold standard confirmatory test of hepatitis C virus (HCV) infection is detection of HCV RNA by PCR. We assessed the utility of HCV core antigen testing to identify active infection among those positive for anti‐HCV antibodies, when introduced to routine testing. We identified serum samples that were tested at a single laboratory in Scotland from June 2011to December 2017. Serum samples testing positive for HCV antibodies (HCV Ab positive) followed by reflex HCV core antigen (Ag) testing during the study period were identified. Those patients for whom a PCR test was requested on the baseline sample were also identified. For this group, the sensitivity and specificity of HCV Ag as a diagnostic tool were assessed using HCV PCR as gold standard. In our cohort of 744 patients, we demonstrated a sensitivity of 82.1% (95% CI 77.1%‐86.2%) and a specificity of 99.8% (95% CI 98.6%‐100%). Genotype 3 was associated with increased odds of a false‐negative result (OR = 3.59, 95% CI: 1.32‐9.71), and reduced odds of a false negative were associated with older age (odds ratio (OR)=0.92, 95% CI: 0.88‐0.97 per year) and viral load (OR = 0.10, 95% CI: 0.05‐0.21 per log10 IU/ml). While the implementation of HCV core antigen testing for diagnosis could lead to significant cost savings in national screening programmes, our data suggest that a significant proportion of HCV‐infected individuals may be missed. These findings have implications for HCV diagnosis and determination of viral clearance after treatment, particularly in low‐ and middle‐income regions, where genotype 3 is prevalent.
- 1 June 2020
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 27 (10) , 996-1002
Open AccessReal‐world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype
Following positive serology, the gold standard confirmatory test of hepatitis C virus (HCV) infection is detection of HCV RNA by PCR. We assessed the utility of HCV core antigen testing to identify active infection among those positive for anti‐HCV antibodies, when introduced to routine testing. We identified serum samples that were tested at a single laboratory in Scotland from June 2011to December 2017. Serum samples testing positive for HCV antibodies (HCV Ab positive) followed by reflex HCV core antigen (Ag) testing during the study period were identified. Those patients for whom a PCR test was requested on the baseline sample were also identified. For this group, the sensitivity and specificity of HCV Ag as a diagnostic tool were assessed using HCV PCR as gold standard. In our cohort of 744 patients, we demonstrated a sensitivity of 82.1% (95% CI 77.1%‐86.2%) and a specificity of 99.8% (95% CI 98.6%‐100%). Genotype 3 was associated with increased odds of a false‐negative result (OR = 3.59, 95% CI: 1.32‐9.71), and reduced odds of a false negative were associated with older age (odds ratio (OR)=0.92, 95% CI: 0.88‐0.97 per year) and viral load (OR = 0.10, 95% CI: 0.05‐0.21 per log10 IU/ml). While the implementation of HCV core antigen testing for diagnosis could lead to significant cost savings in national screening programmes, our data suggest that a significant proportion of HCV‐infected individuals may be missed. These findings have implications for HCV diagnosis and determination of viral clearance after treatment, particularly in low‐ and middle‐income regions, where genotype 3 is prevalent.
- 13 October 2018
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 26 (1) , 93-100
Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awareness‐raising campaign
Summary: The final report of the Penrose Inquiry into historic transmission of HIV and hepatitis C (HCV) through blood transfusion/products in Scotland was published in March 2015 and recommended “everyone who had received a blood transfusion prior to 1991 and who had not had a test for HCV should be offered one.” A targeted awareness‐raising campaign to encourage such individuals to be tested was launched in October 2016. We examined HCV testing undertaken in 2015‐2016 in three NHS boards in Scotland to evaluate impact of these events. Statistical process control was used to monitor trends in individuals tested and those mentioning transfusion. HCV positivity was calculated and multivariate logistic regression was used to examine factors associated with mention of transfusion. A total of 22 842 individuals received an HCV test in 2015‐2016 and 3% of those with clinical information mentioned transfusion. The total number of HCV tests was significantly higher in the week following the Penrose Report and the number mentioning transfusion was significantly higher for three weeks. There was no significant increase following the awareness‐raising campaign. Women and those aged over 50 years were the most likely to have mentioned transfusion. Overall HCV positivity was 3.7% and <1% for the transfusion group. The impact of both intense media coverage and the government‐funded awareness‐raising campaigns in terms of HCV test uptake was modest and short‐lived. Our findings highlight the challenges of case‐finding for HCV and the limited impact of awareness‐raising. This can be used by other countries aiming to identify those infected through historic blood transfusion.
- 13 October 2018
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 26 (1) , 93-100
Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awareness‐raising campaign
Summary: The final report of the Penrose Inquiry into historic transmission of HIV and hepatitis C (HCV) through blood transfusion/products in Scotland was published in March 2015 and recommended “everyone who had received a blood transfusion prior to 1991 and who had not had a test for HCV should be offered one.” A targeted awareness‐raising campaign to encourage such individuals to be tested was launched in October 2016. We examined HCV testing undertaken in 2015‐2016 in three NHS boards in Scotland to evaluate impact of these events. Statistical process control was used to monitor trends in individuals tested and those mentioning transfusion. HCV positivity was calculated and multivariate logistic regression was used to examine factors associated with mention of transfusion. A total of 22 842 individuals received an HCV test in 2015‐2016 and 3% of those with clinical information mentioned transfusion. The total number of HCV tests was significantly higher in the week following the Penrose Report and the number mentioning transfusion was significantly higher for three weeks. There was no significant increase following the awareness‐raising campaign. Women and those aged over 50 years were the most likely to have mentioned transfusion. Overall HCV positivity was 3.7% and <1% for the transfusion group. The impact of both intense media coverage and the government‐funded awareness‐raising campaigns in terms of HCV test uptake was modest and short‐lived. Our findings highlight the challenges of case‐finding for HCV and the limited impact of awareness‐raising. This can be used by other countries aiming to identify those infected through historic blood transfusion.
- 9 June 2017
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 24 (11) , 944-954
Limited impact of awareness‐raising campaigns on hepatitis C testing practices among general practitioners
Summary: The global hepatitis strategy calls for increased effort to diagnose those infected, with a target of 90% diagnosed by 2030. Scotland's Action Plan on Hepatitis C included awareness‐raising campaigns, undertaken during 2008‐2011, to promote testing by general practitioners. We examined hepatitis C virus (HCV) testing practice among general practitioners before and following these campaigns. Scottish general practitioners were surveyed, using Dillman's method, in 2007 and 2013; response rates were 69% and 60%, respectively. Most respondents offer testing when presented with a risk history (86% in 2007, 88% in 2013) but only one‐fifth actively sought out risk factors (19% in 2007, 21% in 2013). Testing was reportedly always/almost always/usually offered to people who inject drugs (84% in 2007, 87% in 2013). Significant improvements in the offer of testing were reported in patients with abnormal LFTs (41% in 2007, 65% in 2013, P<.001) and who had received medical/dental treatment in high prevalence countries (14% in 2007, 24% in 2013, P=.001). In 2013, 25% of respondents had undertaken HCV‐related continued professional development. This group was significantly more likely to actively seek out risk factors (P=.009) but only significantly more likely to offer a test to patients who had received medical/dental treatment in high prevalence countries (P=.001). Our findings suggest that government‐led awareness raising campaigns have limited impact on general practitioners’ testing practices. If the majority of the HCV‐infected population are to be diagnosed, practitioner‐based or physician‐centred interventions should be considered alongside educational initiatives targeted at professionals.
- 9 June 2017
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 24 (11) , 944-954
Limited impact of awareness‐raising campaigns on hepatitis C testing practices among general practitioners
Summary: The global hepatitis strategy calls for increased effort to diagnose those infected, with a target of 90% diagnosed by 2030. Scotland's Action Plan on Hepatitis C included awareness‐raising campaigns, undertaken during 2008‐2011, to promote testing by general practitioners. We examined hepatitis C virus (HCV) testing practice among general practitioners before and following these campaigns. Scottish general practitioners were surveyed, using Dillman's method, in 2007 and 2013; response rates were 69% and 60%, respectively. Most respondents offer testing when presented with a risk history (86% in 2007, 88% in 2013) but only one‐fifth actively sought out risk factors (19% in 2007, 21% in 2013). Testing was reportedly always/almost always/usually offered to people who inject drugs (84% in 2007, 87% in 2013). Significant improvements in the offer of testing were reported in patients with abnormal LFTs (41% in 2007, 65% in 2013, P<.001) and who had received medical/dental treatment in high prevalence countries (14% in 2007, 24% in 2013, P=.001). In 2013, 25% of respondents had undertaken HCV‐related continued professional development. This group was significantly more likely to actively seek out risk factors (P=.009) but only significantly more likely to offer a test to patients who had received medical/dental treatment in high prevalence countries (P=.001). Our findings suggest that government‐led awareness raising campaigns have limited impact on general practitioners’ testing practices. If the majority of the HCV‐infected population are to be diagnosed, practitioner‐based or physician‐centred interventions should be considered alongside educational initiatives targeted at professionals.
- Open Access
- 1 August 2016
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 165, 53-60
Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs
- 1 August 2016
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 165, 53-60
Open AccessHepatitis C reinfection following treatment induced viral clearance among people who have injected drugs